文献速递肾小球疾病

奥妥珠单抗作为原发性膜性肾病初始或二线治疗

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2024-05-13

该回顾性研究纳入59例原发性膜性肾病患者,评估奥妥珠单抗的疗效与安全性。中位随访9.4个月,84.7%患者达到完全或部分缓解,初始治疗缓解率显著高于二线治疗(校正HR 4.5,95%CI 2.1-9.5,P<0.001),未观察到严重不良事件。

要点

  • 奥妥珠单抗治疗原发性膜性肾病缓解率达84.7%。
  • 初始治疗缓解可能性显著优于二线治疗。
  • 所有患者CD19+ B细胞在输注后2周内降至<5 cells/μl。

核心结论

  • 奥妥珠单抗可能是原发性膜性肾病有前景且耐受性良好的治疗选择,尤其作为初始治疗。

研究设计与样本

  • 回顾性分析59例连续的原发性膜性肾病患者,均同意接受奥妥珠单抗并随访至少6个月。

主要发现

  • 50例(84.7%)在中位随访9.4个月期间达到完全或部分缓解。
  • 校正基线eGFR、24小时尿蛋白和抗PLA2R状态后,初始治疗缓解可能性显著高于二线治疗(校正HR 4.5,95%CI 2.1-9.5,P<0.001)。
  • 所有患者输注后2周内循环CD19+ B细胞计数降至<5 cells/μl。
  • 48例PLA2R相关膜性肾病患者中43例血清抗PLA2R浓度降至<14 RU/ml。
  • 奥妥珠单抗给药后24小时尿蛋白显著下降、血清白蛋白显著升高,未观察到严重不良事件。

关键数值与推荐

  • 完全缓解定义为蛋白尿<0.3 g/d。
  • 部分缓解定义为蛋白尿<3.5 g/d且较基线下降≥50%。
  • 20例接受奥妥珠单抗作为初始治疗,39例曾接受至少1种免疫抑制剂作为二线治疗。

临床怎么用

  • 对于原发性膜性肾病患者,可考虑奥妥珠单抗作为初始治疗选择以争取更高缓解概率。
  • 治疗过程中可监测CD19+ B细胞和抗PLA2R抗体水平以评估免疫学应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: B-cell lymphocytes have been demonstrated to play a key role in the pathogenesis underlying membranous nephropathy (MN). The aim of this study was to evaluate the therapeutic efficacy and safety of Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody in individuals with MN. METHODS: We retrospectively analyzed data from 59 consecutive patients with primary MN who provided consent to receive Obinutuzumab and were followed for at least 6 months. The primary outcomes were complete (proteinuria <0.3 g/d) or partial (proteinuria <3.5 g/d with ≥ 50% reduction) remission of proteinuria. RESULTS: Twenty patients received Obinutuzumab as initial therapy, and 39 patients were previously treated with at least 1 immunosuppressant (second-line therapy). Fifty patients (84.7%) achieved complete remission (CR) or partial remission (PR) of proteinuria during the median follow-up of 9.4 months. The likelihood of remission was significantly higher when Obinutuzumab was used as initial therapy than as second-line therapy after adjusting for the baseline estimated glomerular filtration rate (eGFR), 24-hour urinary protein levels, and anti-phospholipase A2 receptor (PLA2R) status (adjusted hazard ratio [HR], 4.5; 95% confidence interval [CI]: 2.1-9.5, P < 0.001). Circulating CD19+ B-cell count decreased to <5 cells/μl in all patients within 2 weeks after infusion. Serum anti-PLA2R concentrations decreased to <14 relative units (RU)/ml in 43 of 48 patients with PLA2R-related MN. After Obinutuzumab administration, a significant reduction in 24-hour urine protein and increase in serum albumin were observed. No serious adverse events were observed. CONCLUSION: Obinutuzumab may represent a promising and well-tolerated therapeutic option for individuals with primary MN. The potential of Obinutuzumab was highlighted as an initial therapy for primary MN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Su X, Wu B, Tie X, et al. Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy. Kidney Int Rep. 2024. PMID: 39156138. doi:10.1016/j.ekir.2024.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。